RxDoctor Payments Data

Mark Woodburn, MD

Family Medicine · Pittsburgh, PANPI 1750566956

Payments from drug & device makers

$637in general payments, 2019–2025

Across 26 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$179
  • Pfizer$80
  • Johnson & Johnson$69
  • Novo Nordisk$50
  • Tosoh Bioscience, Inc.$47
  • AbbVie$40
  • plus $171 from 9 others

What the payments were for

  • Food & beverage$59093%
  • Gifts$477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$637 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$277,639
Medicare patients
564
Services billed
5,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban455$280,013
OzempicSemaglutide68$117,519
JardianceEmpagliflozin120$101,073
XareltoRivaroxaban108$53,470
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$36,265
TrulicityDulaglutide57$32,327
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$24,402
TradjentaLinagliptin44$23,723
EntrestoSacubitril/Valsartan44$19,464
Atorvastatin Calcium1,105$12,862
Memantine Hcl151$12,406
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$12,232
Breo ElliptaFluticasone/Vilanterol20$11,220
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,083
Levothyroxine Sodium938$10,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$280,013455 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$12$130,843177 claims
Novo NordiskOzempic$50$117,51968 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$36$80,887105 claims
Johnson & JohnsonXarelto$69$53,470108 claims
NovartisEntresto$14$19,46444 claims
AbbVieCreon, Synthroid$40$13,253111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →